|
🐜
|
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
21 auth.
T. Mitsudomi,
S. Morita,
Y. Yatabe,
S. Negoro,
I. Okamoto,
J. Tsurutani,
T. Seto,
M. Satouchi,
H. Tada,
T. Hirashima,
...
K. Asami,
N. Katakami,
M. Takada,
H. Yoshioka,
K. Shibata,
S. Kudoh,
E. Shimizu,
H. Saito,
S. Toyooka,
K. Nakagawa,
M. Fukuoka
|
11 |
2010 |
11
🐜
|
|
🐜
|
Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer
24 auth.
J. Soria,
Y. Ohe,
J. Vansteenkiste,
T. Reungwetwattana,
B. Chewaskulyong,
K. Lee,
A. Dechaphunkul,
F. Imamura,
N. Nogami,
T. Kurata,
...
I. Okamoto,
Caicun Zhou,
B. Cho,
Ying Cheng,
E. Cho,
P. Voon,
D. Planchard,
Wu-Chou Su,
J. Gray,
S. Lee,
R. Hodge,
M. Marotti,
Y. Rukazenkov,
S. Ramalingam
|
11 |
2018 |
11
🐜
|
|
🐜
|
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
228 auth.
L. Paz-Ares,
M. Dvorkin,
Yuanbin Chen,
N. Reinmuth,
K. Hotta,
D. Trukhin,
G. Statsenko,
M. Hochmair,
M. Özgüroğlu,
J. Ji,
O. Voitko,
A. Poltoratskiy,
Santiago Ponce,
F. Verderame,
L. Havel,
...
I. Bondarenko,
A. Każarnowicz,
G. Losonczy,
N. Conev,
J. Armstrong,
N. Byrne,
N. Shire,
Haiyi Jiang,
J. Goldman,
E. Batagelj,
Ignacio Casarini,
A. V. Pastor,
S. Sena,
J. Zarbá,
O. Burghuber,
S. Hartl,
B. Lamprecht,
M. Studnicka,
L. Schlittler,
Fabricio Augusto Martinelli de Oliveira,
A. Calabrich,
G. Girotto,
P. Reis,
Carlo Gorini,
Peo Rafael Martins De Marchi,
C. Baldotto,
C. Sette,
M. Zukin,
A. Dudov,
R. Ilieva,
K. Koynov,
R. Krasteva,
I. Tonev,
S. Valev,
V. Venkova,
M. Bi,
Chengshui Chen,
Yuan Chen,
Zhendong Chen,
J. Fang,
Jifeng Feng,
Zhigang Han,
Jie Hu,
Yi Hu,
Wei Li,
Zongan Liang,
Zhong Lin,
R. Ma,
Shenglin Ma,
K. Nan,
Y. Shu,
Kai Wang,
Mengzhao Wang,
Gang Wu,
N. Yang,
Zhi-Xiong Yang,
He-long Zhang,
Wei Zhang,
Jun Zhao,
Yanqiu Zhao,
Caicun Zhou,
Jianying Zhou,
Xiang-dong Zhou,
V. Kolek,
L. Koubková,
J. Roubec,
J. Skřičková,
M. Zemanova,
C. Chouaid,
W. Hilgers,
H. Léna,
D. Moro-Sibilot,
G. Robinet,
P. Souquet,
J. Alt,
H. Bischoff,
C. Grohé,
E. Laack,
S. Lang,
J. Panse,
C. Schulz,
K. Bogos,
E. Csánky,
Anea Fülöp,
Z. Horváth,
Judit Kósa,
I. Laczó,
G. Pajkos,
Z. Pápai,
Zsolt Pápai Székely,
V. Sárosi,
A. Somfay,
É. Ezer,
Anás Telekes,
J. Bar,
M. Gottfried,
N. Heching,
Alona Zer Kuch,
R. Bartolucci,
A. Bettini,
A. Delmonte,
M. Garassino,
M. Minelli,
F. Roila,
S. Atagi,
K. Azuma,
H. Goto,
K. Goto,
Yu Hara,
H. Hayashi,
T. Hida,
Kenya Kanazawa,
S. Kanda,
Y. H. Kim,
S. Kuyama,
T. Maeda,
M. Morise,
Y. Nakahara,
M. Nishio,
N. Nogami,
I. Okamoto,
H. Saito,
M. Shinoda,
S. Umemura,
T. Yoshida,
N. Claessens,
R. Cornelissen,
Lizza Heniks,
Jeroen Hiltermann,
E. Smit,
A. J. S. D. Brekel,
D. Kowalski,
S. Mańdziuk,
Robert Mróz,
M. Wojtukiewicz,
T. Ciuleanu,
D. Ganea,
A. Ungureanu,
A. Luft,
V. Moiseenko,
D. Sakaeva,
A. Smolin,
Alexander Vasilyev,
L. Vladimirova,
Igor Anasina,
J. Chovanec,
P. Demo,
R. Godal,
P. Kasan,
M. Stresko,
M. Urda,
E. Cho,
Joo‐Hang Kim,
Sang-We Kim,
Gyeong-Won Lee,
Jong-Seok Lee,
K. Lee,
K. Lee,
Yun-Gyoo Lee,
M. Molla,
M. D. Gómez,
J. I. D. Mingorance,
D. Casado,
M. L. Brea,
M. M. Tarruella,
T. M. Bueno,
A. N. Mendivil,
Luis Paz-Ares Rodríguez,
S. P. Aix,
M. Campelo,
G. Chang,
Yen-Hsun Chen,
C. Chiu,
T. Hsia,
Kang-Yun Lee,
Chien-Te Li,
Chin-Chou Wang,
Yu-Feng Wei,
Shang‐Yin Wu,
A. Alacacıoğlu,
I. Çiçin,
A. Demirkazık,
M. Erman,
T. Göksel,
H. Adamchuk,
O. Kolesnik,
A. Kryzhanivska,
Y. Ostapenko,
S. Shevnia,
Y. Shparyk,
G. Ursol,
N. Voitko,
I. Vynnychenko,
S. Babu,
A. Chiang,
W. Chua,
S. Dakhil,
A. Dowlati,
Basir Haque,
Rodney Jamil,
J. Knoble,
Shailena Lakhanpal,
Kailhong Mi,
P. Nikolinakos,
S. Powell,
H. Ross,
E. Schaefer,
J. Schneider,
Joseph E. Spahr,
D. Spigel,
J. Stilwill,
C. Sumey,
Michael Williamson
|
10 |
2019 |
10
🐜
|
|
🐜
|
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
17 auth.
T. Seto,
T. Kato,
M. Nishio,
K. Goto,
S. Atagi,
Y. Hosomi,
N. Yamamoto,
T. Hida,
M. Maemondo,
K. Nakagawa,
...
S. Nagase,
I. Okamoto,
T. Yamanaka,
K. Tajima,
Ryosuke Harada,
M. Fukuoka,
N. Yamamoto
|
9 |
2014 |
9
🐜
|
|
🐜
|
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
32 auth.
K. Yonesaka,
K. Zejnullahu,
I. Okamoto,
T. Satoh,
F. Cappuzzo,
J. Souglakos,
D. Ercan,
Andrew H. Rogers,
M. Roncalli,
M. Takeda,
Y. Fujisaka,
Juliet Philips,
Toshio Shimizu,
O. Maenishi,
Y. Cho,
...
J. Sun,
A. Destro,
K. Taira,
K. Takeda,
T. Okabe,
Jeffrey W. Swanson,
H. Itoh,
M. Takada,
E. Lifshits,
K. Okuno,
J. Engelman,
R. Shivdasani,
K. Nishio,
M. Fukuoka,
M. Varella-Garcia,
K. Nakagawa,
P. Jänne
|
9 |
2011 |
9
🐜
|
|
🐜
|
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
12 auth.
M. Socinski,
I. Bondarenko,
N. Karaseva,
A. Makhson,
I. Vynnychenko,
I. Okamoto,
...
J. Hon,
V. Hirsh,
P. Bhar,
Hui Zhang,
J. Iglesias,
M. Renschler
|
9 |
2012 |
9
🐜
|
|
🐢
|
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.
13 auth.
K. Azuma,
K. Ota,
A. Kawahara,
S. Hattori,
E. Iwama,
T. Harada,
Koichiro Matsumoto,
K. Takayama,
S. Takamori,
M. Kage,
...
T. Hoshino,
Y. Nakanishi,
I. Okamoto
|
9 |
2014 |
9
🐢
|
|
🐜
|
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
18 auth.
T. Reungwetwattana,
K. Nakagawa,
B. Cho,
M. Cobo,
E. Cho,
A. Bertolini,
S. Bohnet,
Caicun Zhou,
K. Lee,
N. Nogami,
...
I. Okamoto,
N. Leighl,
R. Hodge,
A. McKeown,
Andrew P. Brown,
Y. Rukazenkov,
S. Ramalingam,
J. Vansteenkiste
|
9 |
2018 |
9
🐜
|
|
🐜
|
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
20 auth.
S. Hironaka,
S. Ueda,
H. Yasui,
T. Nishina,
M. Tsuda,
T. Tsumura,
N. Sugimoto,
H. Shimodaira,
S. Tokunaga,
T. Moriwaki,
...
T. Esaki,
M. Nagase,
K. Fujitani,
K. Yamaguchi,
T. Ura,
Y. Hamamoto,
S. Morita,
I. Okamoto,
N. Boku,
I. Hyodo
|
8 |
2013 |
8
🐜
|
|
🐬
|
Human Ect2 Is an Exchange Factor for Rho Gtpases, Phosphorylated in G2/M Phases, and Involved in Cytokinesis
T. Tatsumoto,
Xiaozhen Xie,
R. Blumenthal,
I. Okamoto,
T. Miki
|
8 |
1999 |
8
🐬
|
|
🦁
|
Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway
8 auth.
I. Okamoto,
Y. Kawano,
Daizo Murakami,
T. Sasayama,
N. Araki,
T. Miki,
...
A. Wong,
H. Saya
|
8 |
2001 |
8
🦁
|
|
🐜
|
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407.
20 auth.
L. Paz-Ares,
D. Vicente,
A. Tafreshi,
A. Robinson,
H. S. Parra,
J. Mazières,
B. Hermes,
I. Çiçin,
B. Medgyasszay,
J. Cid,
...
I. Okamoto,
Sungsook Lee,
R. Ramlau,
V. Vladimirov,
Ying Cheng,
Xuan Deng,
Ying Zhang,
T. Bas,
B. Piperdi,
B. Halmos
|
8 |
2020 |
8
🐜
|
|
🐢
|
Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
14 auth.
K. Ota,
K. Azuma,
A. Kawahara,
S. Hattori,
E. Iwama,
J. Tanizaki,
T. Harada,
Koichiro Matsumoto,
K. Takayama,
S. Takamori,
...
M. Kage,
T. Hoshino,
Y. Nakanishi,
I. Okamoto
|
8 |
2015 |
8
🐢
|
